Figure 6

In vivo IL-1R blockade reduces Th17 cells and inflammation. a) In vivo IL-1R blockade decreased homeostatic Th17 cells. Mice were treated with Anakinra or PBS for 7 days. Single-cell suspensions from different organs were analyzed for Th17 cells. Results are expressed as the percentage of Th17 cells in CD4⁺ T cells ± SEM. *P < 0.05, 5 mice/group. b) In vivo IL-1R blockade reduced DSS-induced Th17 cells. Mice were treated with DSS to induce inflammation and given Anakinra throughout the second cycle of treatment. Single-cell suspensions from different organs were analyzed for Th17 cells. Results are shown as the percentage of Th17 cells in mensenteric lymph node CD4⁺ T cells in mice treated with Anakinra or PBS. Y axis showed SSC and the dot plots were gated on CD4⁺CD3⁺ T cells. n = 4. c-e) In vivo IL-1R blockade prevented polyp formation and ameliorated inflammation induced by DSS. Colon polyps were counted in DSS-challenged IL-10^-/- mice treated with PBS or Anakinra (IL-1Ra). n = 8 mice per group, *P < 0.05 (c). Bloody and polyp-carrying colon sections from untreated mice (top) are shown, but were not observed in IL-1Ra-treated mice (bottom) (d). H&E staining showed heavy cellular infiltration in colon tissue from untreated mice (top), but not in colon tissue from IL-1Ra-treated mice (bottom) (e).